Trial reportAnnals of the rheumatic diseases2014
Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2.
Trial report in Annals of the rheumatic diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00844805 (Infliximab as First Line Therapy in Patients With Early Active Axial Spondyloarthritis Trial), which is not on this map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Infliximab as First Line Therapy in Patients With Early Active Axial Spondyloarthritis Trial
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Brazilian recommendations for the use of nonsteroidal anti-inflammatory drugs in patients with axial spondyloarthritis.Advances in rheumatology (London, England) · 2021Guideline
- [Long version on the S3 guidelines for axial spondyloarthritis including Bechterew's disease and early forms, Update 2019 : Evidence-based guidelines of the German Society for Rheumatology (DGRh) and participating medical scientific specialist societies and other organizations].Zeitschrift fur Rheumatologie · 2019Guideline
- Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis).The Cochrane database of systematic reviews · 2015Pooled it
- The Impact of IL-17A Inhibition in Rheumatic and Musculoskeletal Diseases: Current Insights and Future Prospects.Rheumatology and therapy · 2025Review
- JAK inhibition and axial spondyloarthritis: new steps on the path to understanding pathophysiology.Frontiers in immunology · 2025Review
- Tofacitinib in early active axial spondyloarthritis: protocol of a randomized double-blind, placebo-controlled, multicenter phase IV study, FASTLANE.Therapeutic advances in musculoskeletal disease · 2025Article
- Correspondence on "ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update".Annals of the rheumatic diseases · 2023Article
- A glance into the future of diagnosis and treatment of spondyloarthritis.Therapeutic advances in musculoskeletal disease · 2022Review
- Similarities and Differences Between Juvenile and Adult Spondyloarthropathies.Frontiers in medicine · 2021Review
- Treatment strategies in axial spondyloarthritis: what, when and how?Rheumatology (Oxford, England) · 2020Review
- Treatment of Axial Spondyloarthritis: What Does the Future Hold?Current rheumatology reports · 2020Review
- [Current treatment of axial spondylarthritis : Clinical efficacy].Zeitschrift fur Rheumatologie · 2020Review
- The current standard of care and the unmet needs for axial spondyloarthritis.Rheumatology (Oxford, England) · 2018Review
- Defining the target: clinical aims in axial spondyloarthritis.Rheumatology (Oxford, England) · 2018Review
- Tumor necrosis factor-α (TNFα) inhibitors in the treatment of nonradiographic axial spondyloarthritis: current evidence and place in therapy.Therapeutic advances in musculoskeletal disease · 2017Review
- [Tapering and termination of immunosuppressive treatment in spondyloarthritides (including psoriatic arthritis)].Zeitschrift fur Rheumatologie · 2017Review
- Article
- New evidence on the management of spondyloarthritis.Nature reviews. Rheumatology · 2016Review
- Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies.Therapeutic advances in chronic disease · 2015Review
- Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis.Best practice & research. Clinical rheumatology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate whether biologic-free remission can be achieved in patients with early, active axial spondyloarthritis (SpA) who were in partial remission after 28 weeks of infliximab (IFX)+naproxen (NPX) or placebo (PBO)+NPX treatment and whether treatment with NPX was superior to no treatment to maintain disease control.
methodInfliximab as First-Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial (INFAST) Part 1 was a double-blind, randomised, controlled trial in biologic-naïve patients with early, active, moderate-to-severe axial SpA treated with either IFX 5 mg/kg+NPX 1000 mg/d or PBO+NPX 1000 mg/d for 28 weeks. Patients achieving Assessment of SpondyloArthritis international Society (ASAS) partial remission at week 28 continued to Part 2 and were randomised (1:1) to NPX or no treatment until week 52. Treatment group differences in ASAS partial remission and other efficacy variables were assessed through week 52 with Fisher exact tests.
resultsAt week 52, similar percentages of patients in the NPX group (47.5%, 19/40) and the no-treatment group (40.0%, 16/40) maintained partial remission, p=0.65. Median duration of partial remission was 23 weeks in the NPX group and 12.6 weeks in the no-treatment group (p=0.38). Mean Bath Ankylosing Spondylitis Disease Activity Index scores were low at week 28, the start of follow-up treatment (NPX, 0.7; no treatment, 0.6), and remained low at week 52 (NPX, 1.2; no treatment, 1.7).
conclusionsIn axial SpA patients who reached partial remission after treatment with either IFX+NPX or NPX alone, disease activity remained low, and about half of patients remained in remission during 6 months in which NPX was continued or all treatments were stopped.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.